Bastard, C.; Caumont, C.; Samaison, L.; Quintin-Roué, I.; Doucet, L.; Marcorelles, P.; Le Maréchal, C.; Merlio, J.-P.; Cappellen, D.; Uguen, A.
Fluorescent In Situ Hybridization Testing Allows the Diagnosis of NRG1 Gene Fusions in Lung and Pancreas Cancers with No Other Identified Oncogenic Driver. Cancers 2025, 17, 2347.
https://doi.org/10.3390/cancers17142347
AMA Style
Bastard C, Caumont C, Samaison L, Quintin-Roué I, Doucet L, Marcorelles P, Le Maréchal C, Merlio J-P, Cappellen D, Uguen A.
Fluorescent In Situ Hybridization Testing Allows the Diagnosis of NRG1 Gene Fusions in Lung and Pancreas Cancers with No Other Identified Oncogenic Driver. Cancers. 2025; 17(14):2347.
https://doi.org/10.3390/cancers17142347
Chicago/Turabian Style
Bastard, Clara, Charline Caumont, Laura Samaison, Isabelle Quintin-Roué, Laurent Doucet, Pascale Marcorelles, Cédric Le Maréchal, Jean-Philippe Merlio, David Cappellen, and Arnaud Uguen.
2025. "Fluorescent In Situ Hybridization Testing Allows the Diagnosis of NRG1 Gene Fusions in Lung and Pancreas Cancers with No Other Identified Oncogenic Driver" Cancers 17, no. 14: 2347.
https://doi.org/10.3390/cancers17142347
APA Style
Bastard, C., Caumont, C., Samaison, L., Quintin-Roué, I., Doucet, L., Marcorelles, P., Le Maréchal, C., Merlio, J.-P., Cappellen, D., & Uguen, A.
(2025). Fluorescent In Situ Hybridization Testing Allows the Diagnosis of NRG1 Gene Fusions in Lung and Pancreas Cancers with No Other Identified Oncogenic Driver. Cancers, 17(14), 2347.
https://doi.org/10.3390/cancers17142347
